PURPOSE: Radioligand therapy (RLT) with 177Lu-PSMA-617 is a promising option for patients with metastatic castration-resistant prostate cancer (mCRPC). The present study was designed to define the safety and initial response to a minimal effective injected activity/cycle of 177Lu-PSMA-617 in mCRPC patients. New protective agents for salivary glands and kidney were co-administered and dosimetry was carried out. PATIENTS AND METHODS: A prospective single-arm, open label phase II study on mCRPC was activated at our institute in April 2017. Patients with histologically confirmed advanced mCRPC previously treated with standard life-prolonging agents were enrolled. Folic polyglutamate tablets were orally administered as parotid gland protectors and 500 mL of a 10% mannitol solution was intravenously infused to reduce kidney uptake before the injection of 3.7-5.5 GBq of 177Lu-PSMA-617 repeated four times at interval of 8 weeks. The adsorbed dose calculation was performed with MIRD formalism (OLINDA/EXM software). The Bryant and Day design was used to estimate the sample size taking account of both activity and toxicity. RESULTS: Forty-three eligible patients were evaluated for toxicity and initial response. Dosimetry was carried out in 13 patients. Two (4.8%) patients had G3 and 8 (19.5%) had G2 hematological toxicity. Only 3 (6.9%) patients had mild G1 salivary gland toxicity and 8 (19.5%) had G1 renal toxicity. A decrease of ≥ 30% in prostate-specific antigen (PSA) was achieved after the first cycle in 17 (40.5%) patients, of whom 13 had a PSA decline of >50% after the second cycle. The median adsorbed doses were 0.65 mGy/MBq (range 0.33-2.63) for parotid glands, 0.42 mGy/MBq (0.14-0.81) for kidneys, 0.036 mGy/MBq (0.023-0.067) for red marrow, and 0.038 mGy/MBq (0.018-0.135) for the whole body. CONCLUSION: In advanced, heavily pre-treated mCRPC patients, 3.7 GBq/cycle of 177Lu-PSMA-617 was safe and produced early biochemical and imaging responses at PSMA whole-body scan post injection. Dosimetry of salivary glands suggests that the co-administration of polyglutamate tablets may reduce salivary gland uptake. CLINICAL TRIAL REGISTRATION: EU Clinical Trials Register No.: 2016-002732-32; NCT03454750. Collection and assembly of data: April 2017 and February 2019.
PURPOSE: Radioligand therapy (RLT) with 177Lu-PSMA-617 is a promising option for patients with metastatic castration-resistant prostate cancer (mCRPC). The present study was designed to define the safety and initial response to a minimal effective injected activity/cycle of 177Lu-PSMA-617 in mCRPC patients. New protective agents for salivary glands and kidney were co-administered and dosimetry was carried out. PATIENTS AND METHODS: A prospective single-arm, open label phase II study on mCRPC was activated at our institute in April 2017. Patients with histologically confirmed advanced mCRPC previously treated with standard life-prolonging agents were enrolled. Folic polyglutamate tablets were orally administered as parotid gland protectors and 500 mL of a 10% mannitol solution was intravenously infused to reduce kidney uptake before the injection of 3.7-5.5 GBq of 177Lu-PSMA-617 repeated four times at interval of 8 weeks. The adsorbed dose calculation was performed with MIRD formalism (OLINDA/EXM software). The Bryant and Day design was used to estimate the sample size taking account of both activity and toxicity. RESULTS: Forty-three eligible patients were evaluated for toxicity and initial response. Dosimetry was carried out in 13 patients. Two (4.8%) patients had G3 and 8 (19.5%) had G2 hematological toxicity. Only 3 (6.9%) patients had mild G1 salivary gland toxicity and 8 (19.5%) had G1 renal toxicity. A decrease of ≥ 30% in prostate-specific antigen (PSA) was achieved after the first cycle in 17 (40.5%) patients, of whom 13 had a PSA decline of >50% after the second cycle. The median adsorbed doses were 0.65 mGy/MBq (range 0.33-2.63) for parotid glands, 0.42 mGy/MBq (0.14-0.81) for kidneys, 0.036 mGy/MBq (0.023-0.067) for red marrow, and 0.038 mGy/MBq (0.018-0.135) for the whole body. CONCLUSION: In advanced, heavily pre-treated mCRPC patients, 3.7 GBq/cycle of 177Lu-PSMA-617 was safe and produced early biochemical and imaging responses at PSMA whole-body scan post injection. Dosimetry of salivary glands suggests that the co-administration of polyglutamate tablets may reduce salivary gland uptake. CLINICAL TRIAL REGISTRATION: EU Clinical Trials Register No.: 2016-002732-32; NCT03454750. Collection and assembly of data: April 2017 and February 2019.
Authors: Wesley R Armstrong; Andrei Gafita; Shaojun Zhu; Pan Thin; Kathleen Nguyen; Rejah Alano; Stephanie Lira; Kiara Booker; Linda Gardner; Tristan Grogan; David Elashoff; Martin Allen-Auerbach; Magnus Dahlbom; Johannes Czernin; Jeremie Calais Journal: J Nucl Med Date: 2021-01-28 Impact factor: 11.082
Authors: V Mohan; N M Bruin; M E T Tesselaar; J P de Boer; E Vegt; J J M A Hendrikx; A Al-Mamgani; J B van de Kamer; J-J Sonke; W V Vogel Journal: EJNMMI Res Date: 2021-03-12 Impact factor: 3.138
Authors: Finn Edler von Eyben; Glenn Bauman; Rie von Eyben; Kambiz Rahbar; Cigdem Soydal; Alexander R Haug; Irene Virgolini; Harshad Kulkarni; Richard Baum; Giovanni Paganelli Journal: Int J Mol Sci Date: 2020-11-28 Impact factor: 5.923
Authors: Sazan Rasul; Tim Wollenweber; Lucia Zisser; Elisabeth Kretschmer-Chott; Bernhard Grubmüller; Gero Kramer; Shahrokh F Shariat; Harald Eidherr; Markus Mitterhauser; Chrysoula Vraka; Werner Langsteger; Marcus Hacker; Alexander R Haug Journal: Cancers (Basel) Date: 2021-05-20 Impact factor: 6.639
Authors: Daniel Groener; Cam Tu Nguyen; Justus Baumgarten; Benjamin Bockisch; Karen Davis; Christian Happel; Nicolai Mader; Christina Nguyen Ngoc; Jennifer Wichert; Severine Banek; Philipp Mandel; Felix K H Chun; Nikolaos Tselis; Frank Grünwald; Amir Sabet Journal: EJNMMI Res Date: 2021-07-03 Impact factor: 3.138
Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236